StemCell Therapy

People living with HIV spent a similar amount of time in hospital as HIV-negative COVID-19 patients and had a comparable death rate during the height of the outbreak in New York City, but they were more likely to be put on ventilators, according to a study presented at the23rd International AIDS Conference (AIDS 2020: Virtual) today.

A related study showed that people with HIV had higher levels of inflammation, indicating that they are capable of mounting a strong inflammatory response to the new coronavirus and remain at risk for severe COVID-19 despite taking antiretroviral therapy (ART).

A type of white blood cell that is important in the immune system. Includes B cells (B lymphocytes, which produce circulating antibodies) and T cells (T lymphocytes, which are responsible for cell-mediated immunity).

Halting of the function or replication of a virus. In HIV, optimal viral suppression is measured as the reduction of viral load (HIV RNA) to undetectable levels and is the goal of antiretroviral therapy.

Chemical "messengers" exchanged between immune cells that affect the function of the immune system. Interleukins such as IL-2 are a particular type of cytokine.

When viral load is detectable, this indicates that HIV is replicating in the body. If the person is taking HIV treatment but their viral load is detectable, the treatment is not working properly. There may still be a risk of HIV transmission to sexual partners.

A type of longitudinal study in which information is collected on what has previously happened to people - for example, by reviewing their medical notes or by interviewing them about past events.

Studies have generally found that people with HIV are no more likely to contract the coronavirus (known as SARS-CoV-2) than their HIV-negative counterparts, and they generally do not develop more severe illness or have a higher risk of death. An exception is a study from South Africa that did see increased COVID-19 mortality among HIV-positive people.

Given that people with HIV appear to have a similar risk of contracting SARS-CoV-2 and developing severe illness despite having some degree of immune suppression, some experts and advocates have suggested that antiretrovirals may have a protective effect. However, studies of the effects of HIV medications on COVID-19 outcomes have so far yielded mixed results.

Dr Viraj Patel of Albert Einstein College of Medicine and Montefiore Health System in the Bronx, New York conducted a retrospective cohort study of people with and without HIV who tested PCR positive for SARS-CoV-2 when they were hospitalised between 10 March and 11 May 2020. Montefiore is the largest provider of HIV care in the Bronx, serving more than 4000 people with HIV at four hospitals and 21 primary care clinics.

Located north of Brooklyn and across the river from Manhattan, the Bronx has a largely African-American and Latino population. Over a third of residents were born outside the US and 30% live in poverty among the highest rates in the US. The Bronx was one of the epicentres of the New York City COVID-19 outbreak, which was the worst in the US and among the worst in the world, with more than 300 hospitalisations a day at the peak in early April.

"The likelihood of intubation and death in hospital was higher for people with viral suppression compared to those with uncontrolled HIV."

The researchers looked at length of hospital stays, intubation and mechanical ventilation for respiratory support, development of acute kidney injury and mortality. The analysis did not account for the use of COVID-19 treatments such as remdesivir or steroids.

The analysis included 100 HIV-positive and 4513 HIV-negative people. Just over half were men and the median ages were 62 and 65 years, respectively. Approximately 40% were black, a similar proportion were Latino and 6% were white. Most were on Medicaid (coverage for people with low income) or Medicare (coverage for older people), with only about 15% having private health insurance.

Among the people living with HIV, 94% had been prescribed ART and 81% had a suppressed viral load (below 40 copies/ml). However, about one in five had a CD4 count below 200 cells/mm3, reflecting advanced immune suppression.

The researchers found that most outcomes did not differ between the HIV-positive and HIV-negative patients, including length of stay in hospital (five days in both groups), rates of acute kidney injury or likelihood of death while hospitalised (22% vs 24%, respectively).

However, people with HIV did have a higher rate of intubation and mechanical ventilation21% vs 14%, which worked out to about a 50% greater risk but the difference fell just short of the threshold for statistical significance.

Interestingly, the study found that the likelihood of intubation and death in hospital was higher for people with viral suppression compared to those with uncontrolled HIV. In fact, no one with unsuppressed HIV required intubation or died. People with detectable HIV viral load spent slightly longer in hospital (seven vs five days). But this group only included 15 people, so it is difficult to draw firm conclusions.

In another unexpected finding, having a higher CD4 count before hospitalisation was associated with a higher likelihood of intubation, but no differences in length of stay or risk of death were seen.

"The observation of no intubations or deaths among people living with HIV without viral suppression warrants further examination," Patel and colleagues concluded.

In a separate study, Dr John Hsi-en Ho of the Icahn School of Medicine at Mount Sinai in New York City looked at clinical and immunological characteristics among HIV-positive people with COVID-19.

HIV is characterised by chronic inflammation and varying degrees of immune dysfunction even in people on effective ART, Ho noted as background. COVID-19, too, is associated with abnormal immune function, including low lymphocyte levels.

This retrospective analysis included medical chart data from 93 people with HIV seen at five emergency departments in New York between 2 March and 15 April 2020 who tested PCR positive for SARS-CoV-2.

"People with HIV are capable of mounting a strong inflammatory response to the new coronavirus and remain at risk for severe COVID-19."

Here, 72% of the cohort members were men, 41% were black, 31% were Latino, 23% were white and the median age was 58 years. This study had no HIV-negative control group for comparison.

Participants had a CD4 count of 554 cells/mm3 prior to COVID-19 diagnosis and a nadir or lowest-ever level of 320 cells/mm3. Almost all were on ART, including 70% who used tenofovir disoproxil fumarate or tenofovir alafenamide and 14% who used the protease inhibitors atazanavir (Reyataz), darunavir (Prezista) or lopinavir/ritonavir (Kaletra) drugs that in some studies have shown activity against SARS-CoV-2. More than 80% had an undetectable viral load (below 50 copies/ml).

Upon presentation at the hospital, HIV-positive people with COVID-19 had low total lymphocyte levels and decreased CD4 T cell counts. In contrast, levels of various inflammatory markers were elevated. C-reactive protein (CRP), fibrinogen and D-dimer (a blood clotting marker) were all above the upper limit of normal.

The participants also had much higher than normal levels of the cytokines interleukin 6 (IL-6), IL-8 and tumour necrosis factor alfa, but not IL 1b. Excessive cytokine levels known as a cytokine storm is one of the hallmarks of severe COVID-19 illness that leads to lung and other organ damage.

Looking at differences between 19 HIV-positive people who died of COVID-19 and 53 HIV-positive people who recovered, those who died had hadsignificantly lower total lymphocyte levels compared with survivors. They also had significantly higher peak levels of CRP, IL-6 and IL-8.

However, there was no difference according to pre-diagnosis, current or nadir CD4 counts, whether or not they had undetectable HIV, age, sex or body mass index. Other studies of HIV-negative populations have found that older age, male sex,obesity and other co-morbidities are associated with more severe COVID-19 and higher mortality.

"A subset of people living with HIV are capable of mounting profound inflammatory responses that have been noted to correlate with poor outcomes in people without HIV," the researchers concluded. "These findings raise concerns that people living with HIV remain at risk for severe manifestations of COVID-19 despite ART, and that immune dysregulation in a subset of people living with HIV during infection is associated with worse outcomes."

Ho noted that coronavirus testing was limited during this period and tended to be reserved for sicker patients, so this group is not representative of all HIV-positive people with COVID-19. Further, the proportion of people with HIV suppression was high, so it was not possible to do an informative comparison between those with and without detectable viral load.

Continue reading here:
New York studies look at COVID-19 outcomes and immune function among people with HIV - aidsmap

A national clinical trial this summer will focus on protecting cancer patients against severe COVID-19 infection by attempting to boost their compromised immune system.

Researchers from The Ottawa Hospital say they want to explore the potential of IMM-101, a preparation featuring a dead pathogen containing properties that can stimulate the first-response arm of the immune system.

Study lead Dr. Rebecca Auer, surgical oncologist and director of cancer research at the Ottawa Hospital, says it could help experts understand why some COVID-19 patients are relatively asymptomatic while others end up in intensive care or die.

The difference it seems between these two different presentations has to do with how strong your innate, or your sort of non-specific, first-line defence immune system response is to the virus, Auer said Wednesday.

And so were hoping that by boosting and stimulating this innate immune response, particularly in those vulnerable patients that have a reduced immune response to begin with, wed be able to prevent symptomatic infections and prevent serious infections.

Cancer patients are at much higher risk of severe complications from COVID-19 because chemotherapy, cancer surgery and radiation treatments suppress innate immunity even further.

Auer points to an urgent need to protect them while the world waits for an effective COVID-19 vaccine, which could take another year or more to develop, test, and implement.

A successful trial could also protect cancer patients against other respiratory infections as well as the coming flu season, says Auer, noting the threat of illness is a fairly big problem for those undergoing treatment.

A study demonstrated that about 13 to 15 per cent of cancer patients will have to delay or stop their treatment because of influenza during the average flu season, she says.

And also cancer patients dont respond as well to the influenza vaccine every year because their immune system isnt as strong. So we think that the IMM-101 may in itself be able to help prevent symptomatic influenza infections.

Auer says IMM-101 has also been tested elsewhere for its anti-cancer properties and that, too, will be examined in this trial, although its not the primary objective.

The researchers say the bacteria, Mycobacterium obuense, is safe to use in cancer patients because it has been killed by heat.

The Canadian study will recruit 1,500 patients currently receiving cancer treatment, and participants will be randomly assigned to receive either regular care, or regular care plus IMM-101.

Auer says the treatment would be administered as an injection in the arm, to be followed by two more booster shots.

Researchers will follow patients for a year, watching for any respiratory infections and monitoring whether the treatment works and how long it lasts.

The trials will take place in eight centres located in Ontario, British Columbia and Quebec.

Researchers say people interested in participating should speak with their cancer specialist.

Researchers from the Ottawa Hospital came up with the idea and worked with the Canadian Cancer Trials Group at Queens University to design the trial.

Dr. Chris OCallaghan of the Queens University group notes cancer patients are also at greater risk of COVID-19 infection because they require regular medical care, making it difficult to adhere fully to public health guidelines.

These patients are unable to practice social isolation due to the need to regularly attend hospital to receive critically important cancer treatment, says OCallaghan, who will oversee the trial.

Auer says a successful trial of IMM-101 could also suggest usefulness in treating any patient with a reduced innate immune system, such as older patients with chronic illness.

She notes that the tuberculosis vaccine known as BCG which uses a similar formulation to IMM-101 but uses live bacteria instead of dead bacteria is being tested around the world to see if it can boost the immunity of health-care workers exposed to COVID-19.

Funding and in-kind support, valued at $2.8 million, comes from the Canadian Cancer Society, BioCanRx, the Ontario Institute for Cancer Research, The Ottawa Hospital Foundation, The Ottawa Hospital Academic Medical Organization, ATGen Canada/NKMax, and Immodulon Therapeutics, the manufacturer of IMM-101.

The Canadian Press

Like us on Facebook and follow us on Twitter.

Want to support local journalism? Make a donation here.

Coronavirus

Excerpt from:
Cancer trial to focus on protecting patients from COVID-19 infection - Victoria News

The Sao Paulo patient is a 36-year-old man who finished an antiretroviral therapy treatment to specifically address HIV/AIDS in March 2019. The news raises myriad questions in the scientific community. Additionally, the data are preliminary and the case is particularly compelling because, of the five people who received the treatment, only one has been cured.

Jrgen Rockstroh, professor and doctor of medicine and the head of the outpatient Clinic for Infectious Diseases and Immunology at the Center for Integrated Oncology at the University Clinic in Bonn, said: "These are exciting findings, but they're very preliminary. This has happened to one person, and one person only, but it did not succeed in four others given the same treatment. Clearly, reproducibility of the findings or confirmation in an additional individual would be important."

If the case were proven, it would be a monumental discovery. However, Brazilian scientists say the results are yet to be confirmed, and testing is ongoing.

Why is it so difficult to cure HIV?

HIV inserts its genetic material into the DNA of its target immune cell obliging the cell to form copies of the virus. In this way, the HIV integrates itself directly into the DNA and literally becomes part of its host's body. This makes the virus incredibly difficult to treat.

HIV hides in those cells residing dormant in them for years before it wakes up and causes acquired immunodeficiency syndrome (AIDS). Some scientists believe that the dormant stage is an evolutionary advantage to the virus. In the sites where HIV first enters the body, there are few immune cells to infect.

If the virus destroys all these few existing cells immediately after invasion, there will be no immune cells left to carry the infection to further cells. Rather, the HIV delays its activation until it is carried by those cells initially infected to tissues where it can infect even more cells.

This process ensures a better chance for the virus to spread. This dormant or latent stage can last up to 12 years. After the virus wakes up, the immune system weakens, and AIDS develops. A weakened immune system leaves the patient prone to mild infections that an otherwise healthy individual would likely not develop.

Only two people have been completely cured from HIV

Two patients in London and Berlin underwent a risky bone marrow transplant from a very particular donor, who was discovered to have a natural immunity to HIV. The bone marrow from this individual is immune to the virus due to a mutation in one of the receptors of the immune cells that HIV must be able to enter to successfully cause AIDs.

Before the stem-cell transplantation, doctors destroyed the immune cells carrying the HIV virus in their DNA from the Berlin patient's bone marrow. Later, the naturally mutated stem-cells from the donor were transplanted. The procedure is precarious and can result in life threating conditions, such as graft-versus-host disease, where the body rejects the transplant.

While long-term remission was achieved in these two patients, a bone marrow transplant is not a viable cure for all cases. These patients underwent this experimental treatment to address cancer diagnoses.

How is HIV treated?

Antiretrovirals hinder viral replication, as well as attachment to target cells. The purpose is to stop any viral activity and viral production. Currently, antiretroviral therapy can decrease the viral load in the body to an extent that the person is no longer infectious.

Read more:Stem cell transplants and HIV: What you need to know

If the viral load remains undetectable, one could have unprotected sex without infecting their partner. Moreover, HIV would not be transmitted from a mother to a child in this case. However, if the antiretroviral therapy is stopped, the control of virus replication ends.

The So Paulo patient received antiretrovirals. When asked whether it is possible to expect a complete elimination of a virus which integrates itself in the DNA by antiretroviral drugs, Dr. Rockstroh said, "numerous studies including intensified 3-drug therapy (including maraviroc and dolutegravir given to the Brazilian patient) even very early in HIV-infection were not able to achieve viral elimination or even decrease reservoir over time in multiple clinical trials."

Dr. Rockstroh explained that patients taking post-treatment controllers showed no signs of restarted viral replication for over one year after interrupting anti-retroviral therapy. However, the complete elimination of the virus has not been found in these patients.

How does the immune system react?

The physician added, "As each individual immune system reacts very differently and the spectrum of immune response ranges from rapid disease progression to elite controllers who have no signs of ongoing replication in plasma over years without treatment makes single cases very difficult to generalize from."

The So Paulo patient received a cocktail of antiretroviral drugs, including nicotinamide, a form of vitamin B3, which is thought to wake up the hidden virus and lure it out of its reservoirs. This is done to highlight infected cells for other drugs, so the immune system can kill the virus.

Dr. Rockstroh suggested the approach of virus activation could be significant in finding a functional cure for HIV. Whether this approach works or contributes to this specific case is still unknown.

Scientists are questioning the case and raising the concerns that the patient may have continued to take antiretroviral drugs without the knowledge of the study team. The team commented that they plan to check his blood for antiviral drugs to rule out this possibility.

What is also intriguing about the case is the loss of HIV antibodies. Dr. Rockstroh suggested that the weakening of the antibody test overtime is due to a diminishing immune response. However, the reasons for this remain unclear and require further testing.

Former South African president Thabo Mbeki (1999 - 2008) went down in history as the foremost African denier of AIDS. Against all scientific evidence he maintained that HIV did not cause AIDS. He instructed his health officials to combat the disease with herbal remedies. Experts believe his denialism cost up to 300,000 lives. Some have called for Mbeki to be tried for crimes against humanity.

In 2007 former Gambian president Yahya Jammeh (1996 - 2017) forced AIDS patients to undergo a cure that he had personally developed. It turned out to be a concoction based on herbs; an unknown number of people died. Jammeh, who claimed that he had mystic powers, is the first African head of state to be tried for violating the rights of HIV-positive people.

Another former South African head of state to make headlines for an unconventional take on AIDS was Jacob Zuma (2009 - 2018). After being charged with raping an HIV-positive woman in 2006, Zuma said he was not at risk of infection, despite not using a condom, because he had "taken a shower afterwards." In 2010 he disclosed the negative results of his AIDS test, to fight the stigma, he said.

Ugandas President Yoweri Museveni took his time before joining the fight against the epidemic. As late as 2004, during an international AIDS conference in Thailand, he downplayed the effectiveness of condoms, alleging, among other things, that they ran counter to some African sexual practices. "We dont think we can become universally condomised," he said. His remarks were met with laughter.

Some action taken by African heads of state to fight the scourge did not go down well at home. A tax introduced in 1999 by Zimbabwe's President Robert Mugabe (1987-2017) to help orphans and sufferers met with resistance. It is still in place today. In 2004 Mugabe admitted that his own family had been affected by AIDS. He said the disease was "one of the greatest challenges facing our nation."

Fear of economic repercussions affecting, for example, tourism, is one reason why African leaders have been reluctant to acknowledge the threat. But President Kenneth Kaunda of Zambia (1964-1991) announced as early as 1987 that one of his sons had died of AIDS. In 2002 he was the first African leader to take an AIDS test. He still fights against AIDS today.

The fight against AIDS by Kaundas successor Edgar Lungu met with some hitches when he tried to make AIDS-testing compulsory in Zambia. Lungu said in 2016 that the policy was non-negotiable. But a huge outcry in Zambia and abroad forced him to backpedal especially as the World Health Organization made clear that compulsion encourages the stigmatization of HIV-positive people.

After leaving office, Festus Mogae, former president of Botswana (1998-2008), launched Champions for an AIDS-Free Generation, which brings together a number of former African presidents and other influential personalities eager to help fight the scourge. They hope that their experience and influence will enable them to exert pressure on governments and partners to invest in AIDS prevention.

Author: Cristina Krippahl

Read more here:
Brazilian HIV patient cured: Can this be true? - DW (English)

Global Rheumatoid Arthritis Treatment Market presents insights into the present and upcoming industry trends, enabling the readers to identify the products and services, hence driving the enlargement and effectiveness. The research report provides a comprehensive breakdown of all the major factors impacting the market on a global and regional scale, including drivers, constraints, intimidation, challenges, opportunities, and industry-specific trends. Further, the report cites global certainties and endorsements along with downstream and upstream analysis of leading players.

Get more information on Global Rheumatoid Arthritis Treatment Market Research Report by requesting FREE Sample Copy @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#request_sample

Major Players:

Johnson & JohnsonAmgen Inc.Sobi Inc.UCB S.A.Eli Lilly & CompanySanofi SAAbbVie Inc.Pfizer Inc.Bristol-Myers Squibb CompanyF. Hoffman-La Roche AG

Global Rheumatoid Arthritis Treatment Market research reports enlargement rates and the market value based on market dynamics, growth factors. Complete knowledge is based on the newest innovation in business, opportunities, and trends. In addition to SWOT examination by key suppliers, the report contains an all-inclusive market analysis and major players landscape.

The regional segmentation covers:

Segmentation by Type:

Non-Steroidal Anti-inflammatory Drugs (NSAIDs)CorticosteroidsDisease-modifying anti-rheumatic drugs (DMARDs)

Segmentation by Application:

HospitalRetail PharmaciesDrugstores

Do Inquiry Before Purchasing Report Here and Ask For Discount @: https://www.globalmarketers.biz/discount_inquiry/discount/146290

Report Objectives

Enquire Before Buying : https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#inquiry_before_buying

Table of Content:

The Global Rheumatoid Arthritis Treatment Market

Chapter 1: Rheumatoid Arthritis Treatment Market Overview, Drivers, Restraints and Opportunities

Chapter 2: Rheumatoid Arthritis Treatment Market Competition by Manufacturers

Chapter 3: Rheumatoid Arthritis Treatment Production by Regions

Chapter 4: Production, By Types, Market share by Types

Chapter 5: Consumption, By Applications

Chapter 6: Comprehensive profiling and analysis of Manufacturers

Chapter 7: Manufacturing cost analysis

Chapter 8: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 9: Marketing Strategy Analysis, Distributors/Traders

Chapter 10: Rheumatoid Arthritis Treatment Market Effect Factors Analysis

Chapter 11: Rheumatoid Arthritis Treatment Market Forecast

Chapter 12: Conclusion of Rheumatoid Arthritis Treatment Market

The Report has Tables and Figures Browse The Report Description and TOC @ https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-rheumatoid-arthritis-treatment-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146290#table_of_contents

See original here:
Global Rheumatoid Arthritis Treatment Market Analysis and Forecast 2027- including drivers, constraints, intimidation, challenges, opportunities, and...

Along the way, Dr. Werblin brought in a tech-savvy mobile app developer, Ammad Khan, as a partner. Imagining a concept that would transform somebodys life was very compelling for me, Mr. Khan said.

With $1.5 million from Mr. Dougan, a $1.5 million grant from the National Eye Institute, and about $4 million from angel investors and venture capitalists, the co-founders got to work. They collaborated with experts from Stanford and Johns Hopkins universities, and partnered with Samsung, which provided the smartphone, the augmented, virtual and mixed reality technologies, and the mobile artificial intelligence platform. By 2017, the device was ready.

IrisVision helps restore visual function to people with such conditions as macular degeneration, diabetic retinopathy, retinitis pigmentosis, Stargardt disease, glaucoma and optic atrophy but not cataracts. It can help someone with visual acuity as low as 20/1000. (Acuity measures sharpness: A 20/200 acuity, for example, means a person can make out an object at a distance of 20 feet that a normal vision person could see from 200 feet.)

So how does it work?

IrisVision helps the brain use parts of the eyes that still function properly. The smartphones camera captures an image, and then the virtual reality, or V.R., headset and algorithms enhance the image by providing enough information to fill in the gaps and remap the scene to provide a complete picture.

The company recently added voice control, video streaming, Alexa and other interactive features that give those with low vision easy access to news, weather updates, YouTube videos and TV shows viewed within the headset. The person can adjust the headset, by voice command or button, to zoom in or adjust the color, contrast or brightness.

Still, the device has its shortcomings: It is large and clunky, and the user needs to be stationary not walking around to use it. In addition, at $2,950, it is expensive. And unless you are a veteran, health insurers do not cover the cost.

Read more:
Technology Bridges the Gap to Better Sight - The New York Times

- Advertisement -

Researchers find that pure red light may be enough to recharge a persons vision in life, making them better able to detect colors.The research tasked two dozen people with having a reddish light eye treatment for only 3 minutes daily, and also that short amount of time was sufficient to create quantifiable outcomes.The investigators say this low-cost treatment option could be an easy way for elderly individuals to keep their vision working nicely.

As somebody that has been forced to have cataract surgery at the ripe old age of 35, I understand how big of a bummer it is when our eyes decide that theyve done enough work for a lifetime and start to shut down. We know how a watch can be damaged by light, and how electrons can permanently leave you in the Sun with malfunctioning peepers, however, research indicates that a specific kind of light may have a favorable effect.

The study published in the Journals of Gerontology shows that specific wavelengths of light seem to have a curative effect on aging. More notably, red light in tiny amounts can potentially reverse eyesight problems over time.

Since the scientists describe in their analysis, a total of 24 people were recruited for the research. The volunteers ranged in age, and not one of them had been previously diagnosed. They were each given a particular light that generated.

Easy enough, right? It sounds so straightforward that its hard to imagine it could affect a persons vision one way or another. It did, and the researchers noted that the research participants over the age of 40 showed increases in their capacity to differentiate one color from another, indicating that vision deterioration could be reversed with this straightforward type of light therapy.

As you age, your visual system decreases significantly, especially once more than 40, Professor Glen Jeffery, lead author of the research, said in a statement. your color vision and Your retinal sensitivity are compromised, and this is an issue. To stem or reverse this decline, we sought to reinstall the retinas aging cells with brief bursts of longwave light.

Mitochondria have particular lighting absorbance characteristics influencing their performance, Jeffrey says. Longer wavelengths spanning 650 to 1000nm are consumed and improve mitochondrial performance to boost energy generation. The light given to the volunteers produced light that is 670nm in wavelength, just over the limit to be consumed by the mitochondria andrecharge the eyes.

Our study shows it is likely to significantly improve vision that has declined in aged individuals using easy short exposures to light wavelengths that recharge the energy system which has diminished from the retina tissues, instead of like recharging a battery, Jeffery says.

- Advertisement -

See original here:
Red Light May Be Enough To Recharge a Persons Vision In Life - World Top Trend

An international team of scientists have restored the vision in blind rats using a nanoparticle-based artificial retina prosthesis that can be injected directly into the eye. The scientific advance has been successfully demonstrated for a period of eight months without the need for surgery. While it is still early days for the research, it suggests it might one day be possible to use the conjugated polymer nanoparticle (P3HT-NP) treatment in humans to correct eye problems ranging from hereditary retinal dystrophies to the incredibly common age-related macular degeneration.

In our liquid retina device, P3HT nanoparticles spread out over the entire subretinal space and promoted light-dependent activation of spared inner retinal neurons, recovering subcortical, cortical and behavioral visual responses, Fabio Benfenati, research director at the Italian Institute of Technology, told Digital Trends. We think that P3HT-NPs provide a new avenue in retinal prosthetics.

Retinal prostheses refer to implantable devices that are designed to help restore sight in patients with retinal degeneration. They work by introducing visual information into the retina through the electrical stimulation of surviving retinal neurons. While promising, current retinal prostheses have so far been shown to only return low-resolution vision: Useful for things like distinguishing between light and dark or recognizing simple shapes and objects. This new nanotech approach appears far more promising, offering significantly higher resolution. After just one injection, activity in the rats visual cortex and visual acuity were the same as those found in healthy rats.

As noted, there is still far more research that needs to be carried out before this approach is tried in humans. But Benfenati suggested that this is part of the road map forward.

The most obvious development is to approach the first-in-human application with the current technology that will provide the most complete answers, he said. This will include a step in larger animals and a long-term study of the nanoparticle fate. I foresee that it will require a few years to be accomplished.

A paper describing the work, titled Subretinally injected semiconducting polymer nanoparticles rescue vision in a rat model of retinal dystrophy, was recently published in the journal Nature Nanotechnology.

Link:
Nanotech injections successfully restore vision in blind rats - Digital Trends

Latest market study on Global Vision Care Market Forecast to 2027 COVID-19 Impact and Global Analysis by Product Type (Eye Glasses, Contact Lens, Intraocular Lens, Others); Distribution Channel (Retail Stores, E-Commerce, Clinics, Hospitals).The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Vision Care market during the forecast period, i.e., 20202027. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market on the basis of product type, application, technology, and region. To offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

Request Sample Copy of Vision Care Market at: https://www.theinsightpartners.com/sample/TIPRE00011953/

Vision Care Market In-Depth Analysis:

Vision care is the care and treatment of eyes, eyesight conditions, and vision. The exploding use of electronic devices for everyday functioning has also been related to eye disorders. In recent years, the use of technology has particularly increased among children. Studies suggest excessive use of electronic devices could lead to eye disorders. This indirectly is stoking demand for vision care products.

The vision care market is driving due to the rising geriatric population more susceptible to eye diseases and technological advances in eye care devices. Moreover, the raise awareness for eye health and to address vision-related problems is also serving to boost the vision care market.

Some of the key players profiled in the study are Alcon, Bausch and Lomb, Carl Zeiss, CooperVision, Essilor, Johnson & Johnson, LUXOTTICA GROUP, Rodenstock, Safilo Group, ZEISS, etc.

Key Benefits

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Vision Care market. The researcher provides an extensive analysis of the Vision Care market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Vision Care industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

Scope of the Report

The research on the Vision Care market focuses on mining out valuable data on investment pockets, growth opportunities, and major market vendors to help clients understand their competitors methodologies. The research also segments the Vision Care market on the basis of end user, product type, application, and demography for the forecast period 20212027. Comprehensive analysis of critical aspects such as impacting factors and competitive landscape are showcased with the help of vital resources, such as charts, tables, and infographics.

Promising Regions & Countries Mentioned in The Vision Care Market Report:

Major highlights of the report:

All-inclusive evaluation of the parent market

Evolution of significant market aspects

Industry-wide investigation of market segments

Assessment of market value and volume in past, present, and forecast years

Evaluation of market share

Study of niche industrial sectors

Tactical approaches of market leaders

Lucrative strategies to help companies strengthen their position in the market

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00011953/

Thanks for reading this article; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email: [emailprotected]

Originally posted here:
Vision Care Market Is Booming Worldwide To Generate Massive Revenue | Alcon, Bausch and Lomb, Carl Zeiss, CooperVision - Apsters News

LOS ANGELES, United States: QY Research has recently published a report, titled Global Bionic Eye Market Insights and Forecast to 2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Bionic Eye market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Bionic Eye market include: Retina Implant AG, Bionic Vision Australia, THE BIONIC EYE, Pixium Vision, iBionics, Second Sight Medical Products, NeoStrata Company, ABIOMED, Berlin Heart, Zimmer Biomet Bionic Eye

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1925958/global-bionic-eye-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Bionic Eye market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Bionic Eye Market Segment By Type:

ElectronicMechanical Bionic Eye

Global Bionic Eye Market Segment By Application:

HospitalsClinicsOthers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Bionic Eye market.

Key companies operating in the global Bionic Eye market include Retina Implant AG, Bionic Vision Australia, THE BIONIC EYE, Pixium Vision, iBionics, Second Sight Medical Products, NeoStrata Company, ABIOMED, Berlin Heart, Zimmer Biomet Bionic Eye

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1925958/global-bionic-eye-market

TOC

1 Study Coverage1.1 Bionic Eye Product Introduction1.2 Key Market Segments in This Study1.3 Key Manufacturers Covered: Ranking of Global Top Bionic Eye Manufacturers by Revenue in 20191.4 Market by Type1.4.1 Global Bionic Eye Market Size Growth Rate by Type1.4.2 Electronic1.4.3 Mechanical1.5 Market by Application1.5.1 Global Bionic Eye Market Size Growth Rate by Application1.5.2 Hospitals1.5.3 Clinics1.5.4 Others1.6 Study Objectives1.7 Years Considered 2 Executive Summary2.1 Global Bionic Eye Market Size, Estimates and Forecasts2.1.1 Global Bionic Eye Revenue Estimates and Forecasts 2015-20262.1.2 Global Bionic Eye Production Capacity Estimates and Forecasts 2015-20262.1.3 Global Bionic Eye Production Estimates and Forecasts 2015-20262.2 Global Bionic Eye, Market Size by Producing Regions: 2015 VS 2020 VS 20262.3 Analysis of Competitive Landscape2.3.1 Manufacturers Market Concentration Ratio (CR5 and HHI)2.3.2 Global Bionic Eye Market Share by Company Type (Tier 1, Tier 2 and Tier 3)2.3.3 Global Bionic Eye Manufacturers Geographical Distribution2.4 Key Trends for Bionic Eye Markets & Products2.5 Primary Interviews with Key Bionic Eye Players (Opinion Leaders) 3 Market Size by Manufacturers3.1 Global Top Bionic Eye Manufacturers by Production Capacity3.1.1 Global Top Bionic Eye Manufacturers by Production Capacity (2015-2020)3.1.2 Global Top Bionic Eye Manufacturers by Production (2015-2020)3.1.3 Global Top Bionic Eye Manufacturers Market Share by Production3.2 Global Top Bionic Eye Manufacturers by Revenue3.2.1 Global Top Bionic Eye Manufacturers by Revenue (2015-2020)3.2.2 Global Top Bionic Eye Manufacturers Market Share by Revenue (2015-2020)3.2.3 Global Top 10 and Top 5 Companies by Bionic Eye Revenue in 20193.3 Global Bionic Eye Price by Manufacturers3.4 Mergers & Acquisitions, Expansion Plans 4 Bionic Eye Production by Regions4.1 Global Bionic Eye Historic Market Facts & Figures by Regions4.1.1 Global Top Bionic Eye Regions by Production (2015-2020)4.1.2 Global Top Bionic Eye Regions by Revenue (2015-2020)4.2 North America4.2.1 North America Bionic Eye Production (2015-2020)4.2.2 North America Bionic Eye Revenue (2015-2020)4.2.3 Key Players in North America4.2.4 North America Bionic Eye Import & Export (2015-2020)4.3 Europe4.3.1 Europe Bionic Eye Production (2015-2020)4.3.2 Europe Bionic Eye Revenue (2015-2020)4.3.3 Key Players in Europe4.3.4 Europe Bionic Eye Import & Export (2015-2020)4.4 China4.4.1 China Bionic Eye Production (2015-2020)4.4.2 China Bionic Eye Revenue (2015-2020)4.4.3 Key Players in China4.4.4 China Bionic Eye Import & Export (2015-2020)4.5 Japan4.5.1 Japan Bionic Eye Production (2015-2020)4.5.2 Japan Bionic Eye Revenue (2015-2020)4.5.3 Key Players in Japan4.5.4 Japan Bionic Eye Import & Export (2015-2020)4.6 South Korea4.6.1 South Korea Bionic Eye Production (2015-2020)4.6.2 South Korea Bionic Eye Revenue (2015-2020)4.6.3 Key Players in South Korea4.6.4 South Korea Bionic Eye Import & Export (2015-2020) 5 Bionic Eye Consumption by Region5.1 Global Top Bionic Eye Regions by Consumption5.1.1 Global Top Bionic Eye Regions by Consumption (2015-2020)5.1.2 Global Top Bionic Eye Regions Market Share by Consumption (2015-2020)5.2 North America5.2.1 North America Bionic Eye Consumption by Application5.2.2 North America Bionic Eye Consumption by Countries5.2.3 U.S.5.2.4 Canada5.3 Europe5.3.1 Europe Bionic Eye Consumption by Application5.3.2 Europe Bionic Eye Consumption by Countries5.3.3 Germany5.3.4 France5.3.5 U.K.5.3.6 Italy5.3.7 Russia5.4 Asia Pacific5.4.1 Asia Pacific Bionic Eye Consumption by Application5.4.2 Asia Pacific Bionic Eye Consumption by Regions5.4.3 China5.4.4 Japan5.4.5 South Korea5.4.6 India5.4.7 Australia5.4.8 Taiwan5.4.9 Indonesia5.4.10 Thailand5.4.11 Malaysia5.4.12 Philippines5.4.13 Vietnam5.5 Central & South America5.5.1 Central & South America Bionic Eye Consumption by Application5.5.2 Central & South America Bionic Eye Consumption by Country5.5.3 Mexico5.5.3 Brazil5.5.3 Argentina5.6 Middle East and Africa5.6.1 Middle East and Africa Bionic Eye Consumption by Application5.6.2 Middle East and Africa Bionic Eye Consumption by Countries5.6.3 Turkey5.6.4 Saudi Arabia5.6.5 U.A.E 6 Market Size by Type (2015-2026)6.1 Global Bionic Eye Market Size by Type (2015-2020)6.1.1 Global Bionic Eye Production by Type (2015-2020)6.1.2 Global Bionic Eye Revenue by Type (2015-2020)6.1.3 Bionic Eye Price by Type (2015-2020)6.2 Global Bionic Eye Market Forecast by Type (2021-2026)6.2.1 Global Bionic Eye Production Forecast by Type (2021-2026)6.2.2 Global Bionic Eye Revenue Forecast by Type (2021-2026)6.2.3 Global Bionic Eye Price Forecast by Type (2021-2026)6.3 Global Bionic Eye Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 7 Market Size by Application (2015-2026)7.2.1 Global Bionic Eye Consumption Historic Breakdown by Application (2015-2020)7.2.2 Global Bionic Eye Consumption Forecast by Application (2021-2026) 8 Corporate Profiles8.1 Retina Implant AG8.1.1 Retina Implant AG Corporation Information8.1.2 Retina Implant AG Overview8.1.3 Retina Implant AG Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.1.4 Retina Implant AG Product Description8.1.5 Retina Implant AG Related Developments8.2 Bionic Vision Australia8.2.1 Bionic Vision Australia Corporation Information8.2.2 Bionic Vision Australia Overview8.2.3 Bionic Vision Australia Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.2.4 Bionic Vision Australia Product Description8.2.5 Bionic Vision Australia Related Developments8.3 THE BIONIC EYE8.3.1 THE BIONIC EYE Corporation Information8.3.2 THE BIONIC EYE Overview8.3.3 THE BIONIC EYE Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.3.4 THE BIONIC EYE Product Description8.3.5 THE BIONIC EYE Related Developments8.4 Pixium Vision8.4.1 Pixium Vision Corporation Information8.4.2 Pixium Vision Overview8.4.3 Pixium Vision Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.4.4 Pixium Vision Product Description8.4.5 Pixium Vision Related Developments8.5 iBionics8.5.1 iBionics Corporation Information8.5.2 iBionics Overview8.5.3 iBionics Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.5.4 iBionics Product Description8.5.5 iBionics Related Developments8.6 Second Sight Medical Products8.6.1 Second Sight Medical Products Corporation Information8.6.2 Second Sight Medical Products Overview8.6.3 Second Sight Medical Products Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.6.4 Second Sight Medical Products Product Description8.6.5 Second Sight Medical Products Related Developments8.7 NeoStrata Company8.7.1 NeoStrata Company Corporation Information8.7.2 NeoStrata Company Overview8.7.3 NeoStrata Company Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.7.4 NeoStrata Company Product Description8.7.5 NeoStrata Company Related Developments8.8 ABIOMED8.8.1 ABIOMED Corporation Information8.8.2 ABIOMED Overview8.8.3 ABIOMED Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.8.4 ABIOMED Product Description8.8.5 ABIOMED Related Developments8.9 Berlin Heart8.9.1 Berlin Heart Corporation Information8.9.2 Berlin Heart Overview8.9.3 Berlin Heart Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.9.4 Berlin Heart Product Description8.9.5 Berlin Heart Related Developments8.10 Zimmer Biomet8.10.1 Zimmer Biomet Corporation Information8.10.2 Zimmer Biomet Overview8.10.3 Zimmer Biomet Production Capacity and Supply, Price, Revenue and Gross Margin (2015-2020)8.10.4 Zimmer Biomet Product Description8.10.5 Zimmer Biomet Related Developments 9 Bionic Eye Production Forecast by Regions9.1 Global Top Bionic Eye Regions Forecast by Revenue (2021-2026)9.2 Global Top Bionic Eye Regions Forecast by Production (2021-2026)9.3 Key Bionic Eye Production Regions Forecast9.3.1 North America9.3.2 Europe9.3.3 China9.3.4 Japan9.3.5 South Korea 10 Bionic Eye Consumption Forecast by Region10.1 Global Bionic Eye Consumption Forecast by Region (2021-2026)10.2 North America Bionic Eye Consumption Forecast by Region (2021-2026)10.3 Europe Bionic Eye Consumption Forecast by Region (2021-2026)10.4 Asia Pacific Bionic Eye Consumption Forecast by Region (2021-2026)10.5 Latin America Bionic Eye Consumption Forecast by Region (2021-2026)10.6 Middle East and Africa Bionic Eye Consumption Forecast by Region (2021-2026) 11 Value Chain and Sales Channels Analysis11.1 Value Chain Analysis11.2 Sales Channels Analysis11.2.1 Bionic Eye Sales Channels11.2.2 Bionic Eye Distributors11.3 Bionic Eye Customers 12 Market Opportunities & Challenges, Risks and Influences Factors Analysis12.1 Bionic Eye Industry12.2 Market Trends12.3 Market Opportunities and Drivers12.4 Market Challenges12.5 Bionic Eye Market Risks/Restraints12.6 Porters Five Forces Analysis 13 Key Finding in The Global Bionic Eye Study 14 Appendix14.1 Research Methodology14.1.1 Methodology/Research Approach14.1.2 Data Source14.2 Author Details14.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Continue reading here:
Trending: Bionic Eye Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 | Retina Implant AG, Bionic Vision Australia,...

Of all the things to worry about in the world right now, youd be forgiven if dementiaaka the loss of cognitive functionfailed to make the top of your list. However, dementia is on the rise in the U.S; its most prevalent form, Alzheimers disease, is now the sixth-leading cause of death. So while you shouldnt add this to an increasingly ceaseless inventory of things-which-prevent-sleep, it cant hurt to ever-so-slightly tweak your diet to be more brain health-centric.

Simply put, this means eating more plants, and that includes spices and herbs for brain health. While research is still fairly early stage, Gary W. Small, M.D., director of the UCLA Longevity Center, says that existing studies so far suggest that the antioxidant and anti-inflammatory benefits of certain plants can positively affect brain health.

Plant-based compounds called polyphenols are effective antioxidants, and oxidation is not a good thing in the brain when it creates free radicals that can screw up cellular functioning, says neuroscientist Nan Wise, PhD. Meanwhile, after certain anti-inflammatory drugs, e.g. Aleve or Motrin, were shown to reduce the risk of Alzheimers in older people, Dr. Small and other researchers became interested in safer ways to exert those effects via plants, (since the drugs tend to have side effects).

Below, all the deets on which herbs and spices look promising with respect to brain health based on the existing research, so you can curate your (quarantine) herb garden and spice rack accordingly.

According to Dr. Small, theres epidemiological evidence showing that rates of Alzheimers disease are lower in some parts of the world than otherslike this village in Indiaand one hypothesis is that spicy food contributes to this decreased risk. Particularly, curry, he says. And curry is made made up from curcumin. Curry, ICYMI, gets its curcumin primarily from the spice turmeric.

He put this hypothesis to the test in a small double-blind study,published in the American Journal of Geriatric Psychology, which showed that curcumin did have a significant effect on memory and attention in adults aged 50 to 90 who had mild memory complaints. Over 18 months, curcumin improved memory in this population by 28 percent. They also experienced mild improvements in mood. Though the exact mechanism by which this effect happens is not known, Dr. Small says it likely has something to do with curcumins anti-inflammatory benefits. Dr. Small is currently at work organizing a study that will demonstrate these benefits in a larger cohort.

According to Dr. Wise, the curcumin in turmeric has also been shown to make Docosahexaenoic acid (DHA) more available in the brain. DHA is a form of omega-3 fatty acids that is critical for maintaining brain healthdecreases in DHA in the brain are associated with cognitive decline and Alzheimers onset. As an added bonus, this has mental health benefits, too, as higher DHA levels are associated with lowered anxiety.

What cant turmeric do? A top dietitian explains its many health benefits beyond brain health:

The antioxidant-rich spice saffron has been used medicinally since at least the 7th century BC and today, research is showing it may have neuroprotective benefits. According to Megan Obreiter, RD, clinical dietitian at USC Verdugo Hills Hospital, a small 2010 study showed that a daily dose of 15 milligrams of saffron produced a significantly better effect on cognitive function than a placebo; however, after 22 weeks this effect disappeared. Still, another study out of Iran found that saffron was comparable in efficacy to the Alzheimers drug memantine after one year of use, and another study found that it protected mice from neurotoxins. While more research clearly needs to be done, its not the worst idea to add this spice to your diet if you can afford it, especially given that its extremely delicious. (But if not, no worriesthere are lots of other brain-healthy herbs and spices on this list that are great too.)

Rosemary is one of the best herbs for brain health. Obreiter says it has been shown to improve memory in older adults. Its also been shown to inhibit brain cell deathand protect against neurodegenerative diseases, among other benefits, likely thanks to its anti-inflammatory properties.

Sage has been utilized traditionally for its brain benefits, and studies bear out the wisdom in this approach. Both Obreiter and Dr. Wise mention that the herb has been shown to improve learning and cognition in older adults with mild to moderate Alzheimers. Improved memory in healthy individuals has also been noted.

A 2015 animal study showed that an extract made from cinnamon helped protect lab rats from cognitive impairment, says Dr. Wise. It might also have neuroprotective benefits in Parkinsons patients. Its also long been used to improve circulation and can even potentially help regulate blood sugar levels.

Some research suggests that a nutrient found in the ubiquitous-at-the-holidays spice nutmeg may help improve cognition and memory.

Ginger boasts innumerable benefits to health and has specifically been demonstrated to be useful in treating dementia and Alzheimers disease. Its also great for digestion and fighting inflammation.

Ordinary old pepper is not to be overlooked either, says Wise. Its been shown toimprove memory deficit.

Read this article:
The 8 best herbs and spices for brain health, according to experts - Well+Good

When discussing the greatness of a players NBA career, the overlooked aspect of it seems to be the longevity. Staying on the top level of play requires a certain level of dedication and individual excellence that very few possess, and its an underrated part of ones NBA resume.

Another thing that not many talk about, and players are very proud of is doing it with various organizations. Its a result of a narrative switch from preferably being loyal to one team to now bouncing from one franchise to another. Its a career path no one has a problem with anymore, as precedents for all scenarios have been set. Take, for instance, KD signing with the Warriors. That one will be hard to top.

Many attribute player empowerment to LeBron James. His move to the Heat was a ground-breaking moment for all NBA players the ultimate proof that you are in control of your destiny in the league. James endured the hate for it, and its now a common practice in the league.

Playing in his 17th year in the NBA, LeBron has been a part of three different organizations and has seen the top with two of them. We are still waiting for him to conquer the league with the Lakers, as his championship window is slowly closing.

Nevertheless, his teams have always been elite in terms of winning. That plus his longevity may be the most impressive thing about LeBrons career. Hes been able to do it for so long, no matter the jersey he was wearing, inserting himself in an exclusive group of players who were successful with multiple teams.

However, two players top the group of players who won with multiple franchises. Even James is not yet on their level. One of them youd expect to be there, the other may surprise you. The criterion is recording 200+ wins with three different teams. LeBron still hasnt done it in LA, but will probably do it if he stays with the Lakers long enough, as he is 125 games shy of joining the two.

The first one to ever do it was Wilt Chamberlain. Hes less of a surprise between the two who have ever done it. Wilt first won 231 with the Warriors over six years of playing there. During his four years in Philadelphia, Chamberlain did it again, winning 203 games during the span. He then got traded to the Lakers, where he continued with his impact on the teams success. Wilt won 238 games while wearing purple and gold, becoming the first player ever to do it with three different teams.

There was only one player to do it after Wilt, and its Jason Kidd. Over seven years playing with the Nets, Kidd recorded 292 wins, which is the most games he won with one team during his career. He got exactly 200 with the Suns, which will prove to be key. Kidd also recorded 271 wins over his eight seasons in Texas, playing on and off with the Mavs. He capped his career off with a championship ring, joining one of the most dominant forces in Wilt as the only two who pulled it off.

LeBron is the only one with a realistic chance of getting there. It speaks to the difficulty of accomplishing what both Wilt and Kidd were able to accomplish. But to me, its more of a testimony of how great Kidd really was. Because I expected Wilt to be on the list, Kidds name came as a surprise.

I guess I will leave you with that Kidd deserves more respect than hes getting. Because no matter how great he was, he seems to be underrated in NBA circles. Stuff like this shows you why it shouldnt be the case because just being in any conversation with Wilt and LeBron means youve left a significant mark in the league.

Read more:
THE ONLY TWO PLAYERS TO WIN 200+ GAMES With three different franchises - Basketball Network

He was wounded in Italy during the Second World War and still plays a weekly round of golf and on Thursday, Harry Eisenhauer got one heck of a special 100th birthday.

The Military Museums in Calgary threw a special event for the veteran, which started with a ride in an armoured personnel carrier followed by a military band welcoming him to the party.

"Iwas wounded during the war, fortunately only flesh wounds, so Iwas very lucky there," said Eisenhauer."So all in all, my life has been rather wonderful."

Beyond a bit of luck with those flesh wounds, there could be another factor behind his longevity.

"I had an aunt who lived to 103 and five of my siblings have lived between 94 and 96, and so Iguess good genes is one thing, but I've been very lucky physically," said Eisnhauer.

Eisenhauer's daughter, Janice, says the Military Museums was the right spot for the party, considering so many family members across Canada and in the U.S. couldn't make it to celebrate the milestone.

"It was quite a sad beginning of the planning, because we didn't know how we could make it extra special, but with the military museumwe now have a new family, new friends in Calgary and it's made this a special day," she said.

Eisenhauer's 100th year on Earth will bring one immediate change for him: his driver's license expired at midnight on his birthday and he's not going to renew it.

He says that means he'll have to hitch a ride with someone else for his regular round of golf.

Continued here:
Second World War vet honoured on his 100th birthday - CBC.ca

Hot, humid weather is standard stuff for July in Alabama and Tennessee, but theres some good news for the weekend:

It does look slightly less humid for Saturday!

A weak cool front slides past the Tennessee Valley region early Saturday, and it could reduce the humidity enough to get rid of isolated storms for one more day. We had zero rain Friday; well be close to that again on Saturday (little if any).

Regardless of the small drop in humidity Saturday, the weekend looks hot. Saturday and Sunday do have some significant differences, though:

A weak cold front will approach the Tennessee Valley on Sunday, sparking up thunderstorms along the way. The Severe Prediction Center has a *MARGINAL* Risk of severe weather outlined for north Alabama and south Tennessee.

The SPC defines Marginal Risk as an area of severe storms of either limitedorganizationand longevity, or very low coverage and marginal intensity. In other words, isolated severe storms are possible, but they will be limited in duration, coverage, and/or intensity.

The timeframe for Sundays storms is 2pm to 8pm. The potential impacts include damaging wind gusts as high as 50 mph, heavy rainfall, and frequent lightning.

If a thunderstorm moves in on you this weekend, theres a chance the wind could gust over 35 MPH. It may also bring very heavy rain and intense lightning. Be alert!

Track heavy summer storms with WHNT.coms Interactive Radar or swipe over to the radar feature on Live Alert 19! You can also get up-to-date, location-based alerts wherever you are on Live Alert 19. Download it today for iOS and Android.

Looking for the rest of the forecast? Its always online atWHNT.com/Weatherand in the Daily Forecast section onLive Alert 19!

-JasonConnect with me!FacebookTwitter (@simpsonwhnt)

More:
Weekend heat, humidity and some heavy storms! - whnt.com

When Oumou Sangar tells me freedom is at her core, I am not surprised. If you listen to her discography, you'll be hard-pressed to find a song that doesn't center or in some way touch on women's rights or child abuse. The Grammy award-winning Malian singer has spent a significant part of her career using her voice to fight for the rights of women across Africa and the world, a testimony to this is her naming her debut studio album Moussolou, meaning Woman. The album, a pure masterpiece that solidified Oumou's place amongst the greats and earned her the name 'Songbird of Wassoulou,' was a commercial success selling over 250,000 records in Africa and would in turn go on to inspire other singers across the world.

On her latest body of work Acoustic, a reworking of her critically acclaimed 2017 album Mogoya, Oumou Sangar proves how and why she earned her accolades. The entirety of the 11-track album was recorded within two days in the Midi Live studio in Villetaneuse in 'live' conditionswith no amplification, no retakes or overdubs, no headphones. Throughout the album, using her powerful and raw voice that has come to define feminism in Africa and shaped opinions across the continent, Oumou boldly addresses themes like loss, polygamy and female circumcision.

We caught up with the Malian singer at the studio she is staying while in quarantine to talk about her new album, longevity as an artist, and growing up in Mali.

This interview has been edited and condensed for clarity.

How would you define good music?

What defines good music is the ability for an artist to spread a good spirit and positive energy in it. People will instantly relate to a good soul. The sound of an artist with a good spirit can travel everywhere, even if people don't understand your lyrics.

What was it like growing up in Mali?

After my father took a second wife and abandoned my mother, I had to help her feed the family. I used to sell water in the street, to sing. We were singing together at ceremonies. Even if I had to struggle, I enjoyed growing up in Bamako. That's what has given me strength in life.

Oumou Sangar.Photo: Benoit Peverelli

One thing that has been consistent in your career and discography is your passion for issues that center women and women's rights, has this been a deliberate choice or did you just find yourself singing about this often?

It was a deliberate choice to speak about women's conditions. I couldn't stay silent after having seen so many women suffer around me, starting with my mother's pain. I promised myself that one day I will scream about this problem to the whole world. In my first album Moussolou (the title means Women) I spoke again the abuses of polygamy, arranged marriage, and the inequalities that Malian women endure. I always tried to show that we could do things based on our own decisions and to be autonomous.

What do you think earn singers longevity, especially the type you have?

I think that if you stay natural and sincere with your music, you will manage to keep this longevity. I've always tried to explore new sounds, to get into something new, but being careful, all the while, to respect my culture and tradition from Wassoulou. People will appreciate and recognize your honesty in your craft. You have to never stop working on your thing and to keep faith in what you are doing.

"Mood 4 Eva" from Beyonc's Lion King: The Gift album was quite a moment, what was it like for you?

On its release date, I received a call saying that a sample of my song "Diaraby Nene" was used in "Mood 4 Eva." So, I didn't directly collaborate with Beyonc or the great artists and producers involved in the song. I really like this new version, and we finally found an agreement. I am a big fan of Beyonc. People in Mali were really proud as well. It's great to see that more and more artists are celebrating and sharing African music with us. We built a strong cultural bridge.

What has it been like making your album Acoustic with everything going on in the world?

I recorded my album Acoustic last summer in Paris' suburbs. Even though I made it almost a year ago, the themes and lyrics that I have addressed still resonate with the current situation that we are living in the world now. With this new project, I revisit most of my songs from my previous release Mogoya, which means "people today" or "human relations," I worried about today's relationships between humans both on a personal level and more globally in our society.

Oumou Sangar.Photo: Benoit Peverelli

Tell me about Acoustic, what is the inspiration and story behind it?

After a fully acoustic performance that I gave in London, my record label and I discussed the idea of an unplugged album. They loved the energy on stage, the space it created for my voice, and the raw sound that emerged from the amazing musicians gathered around me. I liked this spontaneous and natural approach, as If you were playing just between friends. It's a way of recording that afforded each musician the joy of reconnecting with the natural sound of his or her instrument. You can hear the purely acoustic sounds of the Wassoulou melodies without embellishments. There are my talented backing singers Emma Lamadji and Kandy Guira, the musical director and great guitarist Guimba Kouyate and Brahima 'Benogo' Diakite, a virtuoso player of the kamele ngoni, who has been with me since my first album Moussolou. Vincent Taurelle from the Parisian collective Albert, joined the band on Ton, toy organ and celesta.

Why are you choosing to release the music now?

With the hard times we are living now, I thought it was a moment where I could bring something to warm hearts and souls. A little something that could help our brothers and sisters in the frontline, those struggling and/or in pain - and make them feel better, whether it be in Mali, in the US or somewhere else in the world.

What do you think the African music industry will look in the next five years?

The whole world is dancing to African music, people are moving on our rhythms and beats. African music is doing very well. I am sure that the African music industry will continue to flourish in the following years. But we need to be careful, and to keep learning on how to organize ourselves and to structure it in order to preserve this priceless wealth and all of our cultural heritage. We have to take care of it, otherwise, it could cost us dearly in the future.

Who would you say are your biggest influences?

My mother is my number one mentor. I learned to sing and to be streetwise from her. I pay tribute to her in the song "Minata Waraba" (Minata the Lioness). I love everything about Bob Marley, his frankness, his music and continuous fight against injustices. We used to dance a lot to "Get Up, Stand Up," even if we didn't understand what he was saying. The emotion in his voice is thrilling. I also really like Miriam Makeba, she has inspired me a lot. A fierce fighter who struggled against apartheid until her last breath. And I listen a lot to Coumba Sidib, a true ambassador of the culture and sound of Wassoulou.

Read more:
Interview: Oumou Sangar Proves Why She's the Songbird of Wassoulou - OkayAfrica

July 10, 2020 When Eva Tsaousidou was in high school, she read something in the newspaper that changed her lifean account of how scientists in Scotland cloned the first-ever mammal, Dolly the sheep.

This was so fascinating to me, recalled Tsaousidou, a postdoctoral fellow in the Department of Molecular Metabolism at Harvard T.H. Chan School of Public Health. It made me want to be part of creating new knowledge in genetics.

Tsaousidou recently told the story about Dolly to a group of high school students in Greece, her home country, through a platform called 100 Mentors that connects scientists virtually to students all over the world. She created a profile on the platform in late 2019 and, in early 2020, got a request from Othisi High School in Athens to talk to groups of students.

In online lectures in February and March this year, Tsaousidou told the students about her research into the connections between obesity, metabolism, and cancer. They found it fascinating, said Tsaousidou. They never thought those two things could overlap. But I told them that in biology and in life, everything is connected, like rings of a chain, and if somehow one thing breaks or doesnt work well, another thing can be affected.

Tsaousidou said the students were excited to learn about her work, and the schools newspaper profiled her in June.

The students dont have a lot of examples of scientists in their life, so they had lots of big questions, she said. One of their questions surprised herthey asked if scientists were able to create human babies in the lab.

I was like, OK, guysno! she said. I told them that wasnt ethical and that scientists have strict regulations.

She was also candid with the students about the demands of the job. The working hours arent 9 to 5, she said, but I told them its very exciting, and every day there is something new and different. And you get a chance to work on things no one has worked on before.

Karen Feldscher

photo: Kent Dayton

See the original post here:
Researcher shares love of science with students in Greece - HSPH News

The Food and Drug Administration has issued a formal warning on several new hand sanitizer products, which comes after numerous reports that adults and children in the United States have been blinded, hospitalized and even died in some instances. The incidents also indicated that people had apparently drunk hand sanitizers that were contaminated with methanol, a highly toxic alcohol.

In an updated safety warning, the FDA identified five more brands of hand sanitizers that contain methanol, which can be poisonous if ingested, inhaled, or simply absorbed through the skin, according to Ars Technica. These new products are in addition to nine methanol-containing sanitizers the FDA identified back in June, all of which are made by the Mexico-based manufacturer Eskbiochem SA de CV. According to FDA testing, one of the products contained 81 percent methanol and no ethanol at all, which is a safe alcohol that's commonly used in hand sanitizers. At the time, the FDA reported that it was "not aware of any reports of adverse events associated with these hand sanitizer products." The five new products are as follows.

The FDA's current warning, which was updated on Monday, indicated that state officials have since reported that "adults and children ingesting hand sanitizer products contaminated with methanol that has led to recent adverse events including blindness, hospitalizations and death." As the agency pushes for recalls, they are advising consumers to stop using the products from Eskbiochem SA de CV immediately and to seek immediate care if there are any signs of poisoning. If any of the products are currently in use, it's recommended they be disposed of in hazardous waste containers, and not down the drain.

Of course, the FDA is still recommending that people wash their hands with soap and water frequently and for at least 20 seconds. In instances where soap and water are not readily available, the Centers for Disease Control and Prevention (CDC) says that hand sanitizer containing an alcohol-base, with at least 60 percent ethanol may be used instead.

Follow this link:
FDA Releases Warning on Hand Sanitizer Products After Reports of 'Blindness' and 'Death' - PopCulture.com

PALO ALTO, Calif., July 10, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases today announced promising additional safety, efficacy and durability data from the ongoing Phase 1b study of its investigational therapy KSI-301, an intravitreal anti-VEGF antibody biopolymer conjugate, in patients with treatment-nave wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and retinal vein occlusion (RVO).

The data are presented online today at the American Society of Retina Specialists 2020 Virtual Annual Meeting by Mark Barakat, M.D., an investigator in the study and physician at Retina Consultants of Arizona, Phoenix, AZ. The study findings presented by Dr. Barakat can be found on the Kodiak Investor Relations website at http://ir.kodiak.com. A livestreamed Q&A panel discussion will be held on Sunday, July 26, 2020, for ASRS Virtual Annual Meeting attendees.

"Now supported by over 100 patient-years of clinical data in the Phase 1b study and over 150 patient-years across the KSI-301 development program, we continue to be very encouraged by the safety, efficacy, and durability of KSI-301," said Jason Ehrlich, M.D., Ph.D., Chief Medical Officer of Kodiak Sciences. "In the data presented today for Virtual ASRS, we observed that 82% of wet AMD eyes and 76% of DME eyes treated with KSI-301 were extended to four months or longer after the last loading dose before receiving their first retreatment. 68% of wet AMD eyes have achieved a six-month interval at least once during follow-up. In DME, with all patients having now been followed for six months or longer after only three initial loading doses (versus the five required with current standard-of-care), it is remarkable that nearly half of patients have yet to require any retreatment, and two-thirds of our DME patients have gone six months or longer before receiving their first retreatment."

"Importantly, KSI-301 is well-tolerated, and the safety profile of KSI-301 remains excellent," continued Dr. Ehrlich. "With 546 doses given in the Phase 1a/1b program, only two events of trace to 1+ intraocular inflammation have occurred, the same two cases as reported previously. These events resolved completely, and both patients have gained over five eye chart lines of vision from their baseline (+30 and +27 letters, respectively). The durability of KSI-301 is exceeding my expectations. It is notable that we see very few retreatment injections in fact, only an average of 1.3 injections were given in the wet AMD patients in the eight months after the loading phase, and only 0.6 injections in DME patients and 1.3 in RVO patients. This compares very favorably to the best current standard-of-care anti-VEGF therapy (4.0, 5.0 and 8.0 injections, respectively). We believe these results strongly support both the disruptive KSI-301 dosing regimens in our pivotal study designs and the studies' likelihoods of success."

"The latest Phase 1b study data, where we see the durability of KSI-301 over longer periods of treatment and follow-up, strongly reinforce the potential for KSI-301 to be a foundational anti-VEGF therapy with a durability profile that patients, physicians and payors are asking for," said Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences. "We believe that a disruptive 'Generation 2.0' anti-VEGF therapeutic would allow nearly all wet AMD and DME patients to be treated on a three-month or longer dose interval and most RVO patients on a two-month or longer interval. Our maturing Phase 1b study data continue to surpass those goalposts. Indeed, for many wet AMD and DME patients, our data suggest KSI-301 may be a once every five- or six-month medicine."

"With all of our pivotal studies enrolling treatment-nave patients similar to those in our Phase 1b, we retain a high confidence in our KSI-301 development program," Dr. Perlroth continued. "Our DAZZLE study in wet AMD, where KSI-301 is given as infrequently as every five-months, continues to recruit well with over 340 patients randomized to date in the US and Europe. We are very appreciative of the support from the ophthalmology community. We look forward to initiating pivotal studies in DME, RVO, and potentially diabetic retinopathy later this year, as we continue advancing KSI-301 on track for our 2022 Vision of a BLA filing in these key indications. We will be discussing these clinical plans in more detail at our July 27, 2020, R&D webinar on the heels of the livestreamed Virtual ASRS panel."

About KSI-301

KSI-301 is an investigational anti-VEGF therapy built on the Company's Antibody Biopolymer Conjugate, or ABC Platform and is designed to maintain potent and effective drug levels in ocular tissues for longer than existing agents. Kodiak's objective with KSI-301 is to develop a new first-line agent to improve outcomes for patients with retinal vascular diseases and to enable earlier treatment and prevention of vision loss for patients with diabetic eye disease. The Company's DAZZLE pivotal study in patients with treatment-nave wet AMD was initiated in October 2019. Kodiak plans to initiate additional pivotal studies of KSI-301 in 2020 in diabetic macular edema, retinal vein occlusion and diabetic retinopathy. These studies are anticipated to form the basis of the Company's initial BLA to support potential approval and commercialization. KSI-301 is being developed and is fully owned globally by Kodiak Sciences Inc. In December 2019, Kodiak entered into an agreement to sell a 4.5% capped royalty right on global net sales of KSI-301 to Baker Bros. Advisors for $225 million.

About the DAZZLE Study

The DAZZLE study (also called Study KSI-CL-102) is a global, multi-center, randomized study designed to evaluate the safety and efficacy of KSI-301 in patients with treatment-nave wet AMD. Patients are randomized to receive either KSI-301 on an individualized dosing regimen as infrequently as every five months and no more often than every three months or to receive standard-care aflibercept on its every eight-week dosing regimen, each after three monthly initiating doses. The primary endpoint is at one year and each patient will be treated and followed for two years. Additional information about DAZZLE can be found on http://www.clinicaltrials.gov under Trial Identifier NCT04049266 (https://clinicaltrials.gov/show/NCT04049266).

About the KSI-301 Clinical Program

The KSI-301 Clinical Program is designed to assess KSI-301's safety, efficacy and durability in wet AMD, DME, RVO and non-proliferative DR (without DME) through clinical studies run in parallel. We have agreed on the order and number of clinical studies required to support the licensure of KSI-301 in wet AMD, DME, RVO and non-proliferative DR at an end of phase 2 meeting with the U.S. Food and Drug Administration (FDA). We confirmed that two clinical studies conducted in a single indication are expected by FDA to demonstrate the initial safety and efficacy of KSI-301. One clinical study each in the additional disease indications, if successful, can be used to support approval in the additional indications. We intend to conduct two Phase 3 studies in DME (the GLEAM and GLIMMER studies) to provide the mutually confirmatory studies required by FDA for initial demonstration of safety and efficacy. We also intend to conduct one study in wAMD (our ongoing DAZZLE study) and one study in RVO (the BEACON study) to support approval of these additional indications. We intend to file this package together in a single BLA in 2022. We also plan to run an additional study in patients with non-proliferative DR without DME (the GLOW study) which depending on data readiness may be combined either into the single initial BLA or may be filed as a supplemental BLA. We expect that the global KSI-301 clinical program will be conducted at 100+ study sites in more than 10 countries.

About Kodiak Sciences Inc.

Kodiak (Nasdaq: KOD) is a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases. Founded in 2009, we are focused on bringing new science to the design and manufacture of next generation retinal medicines to prevent and treat the leading causes of blindness globally. Our ABC Platform uses molecular engineering to merge the fields of antibody-based and chemistry-based therapies and is at the core of Kodiak's discovery engine. Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration, a leading cause of blindness in elderly patients, and diabetic retinopathy, a leading cause of blindness in working-age patients. Kodiak has leveraged its ABC Platform to build a pipeline of product candidates in various stages of development including KSI-501, our bispecific anti-IL-6/VEGF biopolymer conjugate for the treatment of neovascular retinal diseases with an inflammatory component, and we are expanding our early research pipeline to include ABC Platform based triplet inhibitors for multifactorial retinal diseases such as dry AMD and glaucoma. Kodiak is based in Palo Alto, CA. For more information, please visit http://www.kodiak.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding our belief that KSI-301 may achieve disruptive dosing regimens; the likelihood of success of our KSI-301 Clinical Program; the potential for KSI-301 to be a foundational anti-VEGF therapy with a durability profile that patients, physicians and payors will seek; our ability to initiate pivotal studies in DME, RVX and potentially diabetic retrinopathy in 2020; our ability to achieve our 2022 Vision, including a single BLA submission in wet AMD, DME, RVO and diabetic retinopathy in 2022; our platform technology and potential therapies; future development plans; clinical and regulatory objectives and the timing thereof, anticipated design of planned clinical trials, expectations regarding the potential efficacy and commercial potential of our product candidates; the anticipated presentation of data; the results of our research and development efforts and our ability to advance our product candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "pursue," and other similar expressions among others. Any forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the preliminary safety, efficacy and durability data for our KSI-301 product candidate will not continue or persist; cessation or delay of any of the ongoing clinical studies and/or our development of KSI-301 may occur; future potential regulatory milestones of KSI-301, including those related to current and planned clinical studies may be insufficient to support regulatory submissions or approval; anticipated presentation of data at upcoming conferences may not occur; our research and development efforts and our ability to advance our product candidates into later stages of development may fail; any one or more of our product candidates may not be successfully developed, approved or commercialized; adverse conditions in the general domestic and global economic markets; as well as the other risks identified in our filings with the Securities and Exchange Commission. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our most recent Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof and Kodiak undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Kodiak, Kodiak Sciences, ABC, ABC Platform and the Kodiak logo are registered trademarks or trademarks of Kodiak Sciences Inc. in various global jurisdictions.

SOURCE Kodiak Sciences Inc.

Home

Excerpt from:
Kodiak Sciences Announces New Longer-Term Safety, Efficacy and Durability Data from Ongoing Phase 1b Study of KSI-301 in Patients with Wet Age-Related...

Global Facial Injectable Market Share, Growth and Trends Analysis by Type (Botulinum Toxin, Hyaluronic Acid, Polymers and Particles and Collagen), Application (Facial Line Correction Treatment, Face Lift and Lip Treatments), End User (Hospitals, Specialty Clinics and Spa & Beauty Clinic) and Region (North America, Europe, Asia-Pacific and Middle East & Africa) Forecast till 2025

Anti-ageing, face rejuvenation and cosmetic treatments have changed the rules of engagement and reinvention. Today, its possible to change the basic elements of yourself to fulfil the basic desire of humans to be young.

Thefacial injectable marketis been driven by numerous factors. However rising proportion and absolute numbers of older people led by baby boomers generation with good incomes are the critical driving factor for the global facial injectable market. According to the World Health Organization estimates between 2015 and 2050, the proportion of the worlds population over 60 years will double from 12% to 22% which will be a positive development for the market.

Another critical driver and the motive behind the market is the primal desire to remain young. The extension of life has been a primal desire of humanity and a mainstay motif in the history of scientific pursuits and ideas throughout history, from the Egyptian Smith medical papyrus, Ayurveda practitioners, alchemists, etc. This primal desire for youth has driven the market for anti-ageing drugs since time immemorial.

Request Free Sample Copy at:https://www.marketresearchfuture.com/sample_request/1527

The growing influence of lifestyle, fashion and film industry have led to rising demand of medications to slow the ageing and its signs. Health and youth wellness have become a status symbol and youthful appearance is penetrating peoples life and there is increasing consumerization of youth. The growth of media such as television and lifestyle magazines have led to a craze for youthful appearance.

Other driving factors are primal desire of humans to remain young, influence of lifestyle industry and rising awareness about wellbeing, high levels of disposable incomes etc. The market restraints are skepticism and concerns of safety regarding the unrestricted use of anti-ageing drugs without greater and clearer experimental validation. Ambiguity of the definition of anti-ageing drugs is also a cause of concern. For example, numerous cosmetics have been included or claimed to have anti-aging effects and have been termed as Cosmeceuticals. Cosmeceutical is defined by the cosmetic industry as cosmetic products that have medicinal or drug like effects which is not supported by the U.S. Food and Drug Administration (FDA) or the Food, Drug and Cosmetic Act.

The facial injectable market is a technological oriented market having a high research and development potential due to advancement in technologies and cellular understanding which are keys to unravel the exact mechanism of ageing. Gene therapy, stem cell technology and targeted delivery of nutrients using biotechnology are expected to open the gates for anti-ageing drugs. The development of biomarkers for physiochemical modifications in the body such as alteration of concentration of an enzyme or hormone provides another exiting avenue for the future market. For example, levels of homocysteine has been proposed as a marker of age related changes in the body so as to compensate the change by drugs.

From a market perspective the facial injectable market is ripe with mergers, acquisitions and partnerships. For example, in 2017, cosmetic giant LOral acquired skincare brands such as CeraVe, AcneFree and Ambi from Valeant Pharmaceuticals at ~ $1.25 billion. In 2016, Johnson & Johnson acquired Vogue International LLC, for greater than $3 billion to strengthen its consumer segment. Thus, partnerships seem to be a good strategy to curtail the developmental cost of any new facial injectable drug. Acquisition of other companies also leads to expansion of product lines which improves market penetration and exposure.

The global market for facial injectable is expected to reach USD 9.04 billion by the end of the forecasted period 2023 and is expected to grow at a CAGR of 13.2%

Global facial injectable market is segment by types and applications. Based on types the market is sub-segmented as botulinum toxin, hyaluronic acid, polymers & particles, and collagen. On the basis of application, the market is sub-segmented into facial line correction treatment, face-lift, lip treatments and others.

The key players in his market are Allergan, Galderma, Integra Lifesciences, Merz Pharma, Sanofi, SciVision Biotech Inc, Sinclair. Suneva Medical and Valeant Pharmaceuticals.

Regional outlook for the facial injectable market

The facial injectable market is dominated by North America. The U.S. is the prime mover of the facial injectable market. However, it has to be noted that Latin America despite its lower per capita income has a disproportionate share of the market. It is estimated that Latin America will be the fastest in the future. As of the present the European regions is expected to be the second largest market globally, with countries like Germany, UK and France playing a prominent role in the market. Germany accounts for both the largest and the fastest growing nation in the European region facial injectable market, followed by France.

Asia Pacific market is expected to be the fastest future growing market during the forecast period 2016-2023. The Asia Pacific region will be led by countries such as China and India. However the greatest hindering reasons for the Asia pacific region market is the poor per capita income and the high cost of treatment. Nations such as Thailand etc. have a disproportionate share of Asia Pacific market considering their low income as compared to the U.S. The market of these nations is influenced to a considerable degree by the tourism and fashion industry. Advertisement and greater exposure seems to be the best strategy to be a market leader along with product development. The return on investment for advertisement and publicity is very high for the cosmetic surgery market.

There has been a definite shift of the cosmetic surgery market from the developed regions to the developing ones particularly Latin America and Asia Pacific countries such as Thailand. The market represents a clustered outlook with urban metropolitan cities especially with adjoining tourism and fashion industry having an extreme lead over the rural areas. Large tourism clusters such as Miami, Bangkok, Bali etc. have a disproportionate share of the market due to the large volume of cosmetic surgeries.

The porn industry also is affecting the market and it has been seen that the rise of cosmetic surgeries has a linear relationship with the quality and bandwidth of the internet. Thus cities such as Los Angeles, Las Vegas etc. are the leading clusters of cosmetic surgery market.

Browse Complete Research Report with COVID-19 Impact Analysis at:https://www.marketresearchfuture.com/reports/facial-injectable-market-1527

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [emailprotected]

Follow this link:
Facial Injectable Market Growth Analysis, Size Projection, Key Insights, COVID-19 Impact Analysis and Future Trends By 2025 - Cole of Duty

Jennifer Carroll Foy

by James A. Bacon

Hispanics make up 9% of Virginias population but 43% of the states COVID-19 cases. So, it seems a not-unreasonable thing for Del. Jennifer Carroll Foy, D-Prince William, a candidate for governor, to call upon Governor Ralph Northam to increase funding for outreach over Spanish-language media to build public awareness about the virus.

But then in her letter to the governor, she said some things that arent so reasonable: The rates of infection are alarming, and magnify the inequities that are staring us in the face. They stem from longstanding and systemic factors, such as disparate access to information, testing, and treatment.

Here we go again: inequities, systemic factors and disparate access. It is so widely assumed that Virginia is a hellhole of inequity and prejudice that no one even tries to prove statements like Foys. (Shes hardly alone in making them.) The allegations are accepted without question.

Lets take a look at the numbers. The first thing to note is that the Hispanic population in Virginia has surged over the past two decades from 239,000 in 2000 to 619,000 this year. Most of this increase was driven by immigration into the state. It is safe to assume that a large percentage come from poor countries in search of economic opportunity. With little education, most immigrants sought employment in occupations requiring manual skills. As a consequence, to quote Virginia Public Media, 85% of Latinos cant work at home. They must leave their houses to go to work and get paid, which makes them more likely to be exposed to COVID-19.

After accepting thousands of poor, low-skilled Hispanic newcomers from other countries, providing them jobs, education, healthcare and other services over the past 20 years, Virginia suddenly is guilty of systemic inequities. Hispanic immigrants didnt metamorphose from impoverished villagers overnight into prosperous middle-class Americans who can work safely at home on their computers, so we are stained by inequity!

How have we supposedly failed our Hispanic citizens and residents? Foy suggests that Latinos have inadequate access to testing. What evidence does she have that Latinos are any less likely to be tested than blacks, whites, or Asians? She presents none in the letter. But consider this: 43% of all Virginians found to carry the COVID-19 virus(whose race is known) are Hispanics. How do we come by this statistics? Its because they were tested! Someone, somewhere, somehow, tested them.

If Latinos consistently tested positive for the virus at higher rates than other groups say, that 20% of Hispanics tested positive, while for other groups only 10% tested positive it might suggest that only the sickest Hispanic patients with the most visible symptoms were being tested, and that Hispanics generally were being under-tested. But the Virginia Department of Health doesnt break out data on the number of tests administered by race/ethnicity, so we cant tell. Perhaps VDH has that data, but it does not publish it on its COVID-19 dashboard. Of one thing we can be reasonably certain, Foy has not crunched those numbers. If she had, she would have cited them. Basically, shes just making stuff up.

Now, lets talk about access to the health care system. Hispanics account for 35% of all hospitalizations in the state. Despite Virginias systemic inequities, somewhere, somehow, 2,277 Hispanic COVID-19 patients so far have managed to find hospitals to take care of them. One possible retort is that 35% of all hospitalizations is lower than 43% of all confirmed cases, therefore, some Latinos might have been denied access to hospitals. That discrepancy is easily explained: The Hispanic population skews younger that than of other racial/ethnic groups. Because they are younger on average, fewer experience symptoms severe enough to require hospitalization.

Well, surely Hispanics are getting second-class treatment when they wind up in the hospital. Not so. While accounting for 35% of all hospitalizations in Virginia, Hispanics account for only 11.4% of deaths. That suggests to me that the health care provided Latinos is pretty darn good, and that any insinuation otherwise is a slur and a slander on Virginia doctors, nurses, hospital administrators and other providers.

Bacons bottom line: There is no statistical evidence in the public domain that Virginia Hispanics are tested less for COVID-19, that Hispanics infected by the virus enjoy less access to hospitals, or that Hispanic patients receive inferior treatment in any way. Perhaps such evidence does exist. But Foy doesnt cite it. It is reckless and irresponsible to spout off about inequities, systemic factors and disparate access without any supporting proof. Of course, she is hardly the only one to make such claims I single her out only because her letter has been widely quoted in the media. But repeating an unsubstantiated claim over and over and over does not make it true.

Related

Visit link:
Are Hispanics Victims of Inequities in COVID-19 Epidemic? - Bacon's Rebellion

Calgary, Alberta--(Newsfile Corp. - July 10, 2020) - Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) ("Hemostemix" or the "Company") today filed on SEDAR its audited Financial Statements and Management Discussion and Analysis for the annual period and fourth quarter ending December 31, 2019 and for the comparable periods ending December 31, 2018.

ABOUT HEMOSTEMIX

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years.

The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit http://www.hemostemix.com.

Contact: Thomas Smeenk, President, CEO & Co-FounderTSmeenk@Hemostemix.com 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the commercialization of ACP-01. There can be no assurances that such forward-looking information will prove to be accurate, and actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix which the Company believes are reasonable. These assumptions include, but are not limited to: the results of ACP-01 research, trials and studies being equivalent to or better than previous research, trials or studies as well as management's expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory approvals for research, trials or studies as well as any required or desired financings of Hemostemix, including TSX Venture Exchange acceptance and any third party consents; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete a satisfactory futility analysis and the results of such and future clinical trials; litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in the Company's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, economic activity financing, supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession; the potential impact that the COVID-19 pandemic may have on Hemostemix may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

Story continues

View post:
Hemostemix Files Its Audited Annual Financial Statements and Management Discussion and Analysis for the Period Ending December 31, 2019 - Yahoo...